Since the beginning of 2021, more than 200 senior executives in the pharmaceutical industry have resigned!

Less than a week after the start of December, the wave of resignations in the pharmaceutical industry continued
.
On December 3, 2021, Huaren Pharmaceutical issued an announcement regarding the resignation of the company’s senior management staff.
The board of directors recently received the resignation report of the company’s CEO, Ms.
Chu Xiaojun
.
The announcement shows that because Ms.
Chu Xiaojun has reached the statutory retirement age and has gone through the retirement procedures, she has applied to resign as CEO and other positions.
After her resignation, she will no longer continue to serve in the company and its subsidiaries
.
According to the company's 2020 annual report, Chu Xiaojun received a total of 866,000 yuan of pre-tax remuneration from the company
.
As of the date of this announcement, Ms.
Chu Xiaojun holds a total of 960,000 shares in the company, and she promises to manage the shares held in strict accordance with the relevant regulations on the transfer of directors, supervisors, and senior executives
.
Public information shows that Huaren Pharmaceutical is a state-owned pharmaceutical and health industry group integrating production, learning, and research.
It is mainly engaged in large infusions (including non-PVC soft bags, vertical soft bags, plastic bottles, and large glass infusions) , Peritoneal dialysate, respiratory system drugs, fine anesthesia drugs and raw materials, supporting pharmaceutical packaging materials, medical equipment, research and development, production and sales of major health products
.
The company’s disclosed third quarter report for 2021 showed that the company’s main operating income was 4.
097 billion yuan, an increase of 304.
53% year-on-year; net profit attributable to the parent was 117 million yuan, a year-on-year increase of 116.
82%; non-net profit deducted 112 million yuan, a year-on-year increase of 139.
73%; among them, In the third quarter of 2021 alone, the company's main operating income was 1.
572 billion yuan, an increase of 268.
62% year-on-year; the net profit attributable to the parent was 43.
798 million yuan, an increase of 130.
63% year-on-year
.
Since 2021, executives in the pharmaceutical industry have undergone frequent changes
.
Among them, in the first half of November, there were personnel changes in the executives of more than 18 companies, involving Pfizer, AstraZeneca, Ruizhi Pharmaceutical, Tianjing Biological, Ascent Pharmaceuticals, WuXi Biologics, Sinopharm, Kangzhi Pharmaceutical, Domestic and foreign pharmaceutical companies such as Jinshiya, Hengrui Pharmaceuticals, and Lexin Medical have involved the resignation of multiple chief financial officers and chief commercial officers, and the change of (vice) chairman of the board
.
In October, about 22 pharmaceutical companies’ senior management positions changed, involving many positions such as general manager and vice president
.
The pharmaceutical companies involved include BeiGene, Lisheng Pharmaceutical, Stellite, AstraZeneca, etc.
The reasons for resignation include work reasons, personal reasons, and adjustments to the division of labor
.
In September, at least 7 senior executives of pharmaceutical companies resigned.
The positions involved included chairman, vice president, deputy general manager and other positions.
The companies involved included Stellite, Hanhui Pharmaceutical, Fosun Pharma, BeiGene, and Ogilvy.
medical, Gan & Lee Pharmaceutical and so on
.
In the first half of 2021, a total of 128 senior executives in the pharmaceutical industry have resigned, a year-on-year decrease of approximately 20% compared with the approximately 160 senior executives in the pharmaceutical industry in the first half of 2020
.
According to incomplete statistics in the industry, since the beginning of the year, more than 200 senior executives in the pharmaceutical industry have resigned
.
Judging from the positions that have undergone personnel changes this year, the positions of vice president, general manager, deputy general manager, secretary of the board of directors, and chief financial officer/director have changed a lot
.
Take the board secretary as an example.
Fung Huashun data shows that there are 107 pieces of data related to the resignation of board secretaries of 71 companies, and 49 pieces of information are resignation information
.
In addition, with regard to the position of the person in charge of finance/director, 85 companies have released resignation information since 2021, and a total of nearly 60 people have resigned
.
From the perspective of the industry, the constant changes in pharmaceutical company executives are related to the tremendous pressure faced by the pharmaceutical industry
.
Under the changing pattern of the pharmaceutical market, many pharmaceutical companies have to seek new marketing models, accelerate their transformation and upgrading, and accompanied by frequent changes in executives
.